Eloralintide: all 24 studies that test it

Page 1 of 1. Open to participants first (14), then studies with results posted, then the rest; newest registration first within each.

• A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 DiabetesNot yet recruitingNCT07881458Phase 3
• A Study of EloraTZP in Adult Participants With Obesity Without Type 2 DiabetesNot yet recruitingNCT07881432Phase 3
• A Study of Eloralintide (LY3841136) in Female Participants With Obesity or OverweightRecruitingNCT07808060Phase 1
• A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 DiabetesNot yet recruitingNCT07765511Phase 1
• A Study of Eloralintide (LY3841136) in Participants With Obesity or OverweightRecruitingNCT07738614Phase 1
• A Study of Eloralintide (LY3841136) in Participants With Overweight or ObesityRecruitingNCT07665879Phase 1
• A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OverweightRecruitingNCT07589608Phase 2
• A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.RecruitingNCT07401862Phase 1
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinRecruitingNCT07392190Phase 3
• A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightRecruitingNCT07369011Phase 3
• Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightRecruitingNCT07353931Phase 3
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesRecruitingNCT07321886Phase 3
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesRecruitingNCT07282600Phase 3
• A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightRecruitingNCT06143956Phase 2
• A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or OverweightCompletedNCT06230523Phase 2Results posted
• A Study of Eloralintide (LY3841136) in Healthy ParticipantsActive, not recruitingNCT07701083Phase 1
• A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal FunctionActive, not recruitingNCT07426380Phase 1
• A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesActive, not recruitingNCT07215559Phase 2
• A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or OverweightCompletedNCT06916091Phase 1
• A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or ObesityCompletedNCT06916065Phase 1
• A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesCompletedNCT06603571Phase 2
• A Study of LY3841136 in Overweight and Obese ParticipantsCompletedNCT06345066Phase 1
• A Study of LY3841136 in Japanese Participants With Obesity or OverweightCompletedNCT06297616Phase 1
• A Study of LY3841136 in Healthy and Overweight ParticipantsCompletedNCT05295940Phase 1

← Eloralintide overview